In the study, Enhertu reduced the risk of disease progression or death by 36% compared with chemotherapy in 866 patients with chemotherapy-naïve, HR-positive, HER2-low or -ultralow metastatic breast ...

Under the new indication, eligible patients can receive Enhertu after endocrine therapy, without first undergoing chemotherapy. The decision was supported by data from the Phase ... to 8.1 months ...

DESTINY-Breast06 is a global, randomised, open-label, Phase III trial evaluating the efficacy and safety of Enhertu (5.4mg/kg) versus investigator’s choice of chemotherapy (capecitabine, paclitaxel or ...

The FDA approval of AstraZeneca’s sBLA was based on positive data from the phase III DESTINY-Breast06 study, which compared Enhertu to chemotherapy ... as compared to 8.1 months for chemotherapy.